In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.
The FDA has expanded the approval of Fasenra (benralizumab; AstraZeneca) to include self-administration with the Fasenra Pen, a prefilled, single-use autoinjector. The Food and Drug Administration ...
FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...
Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...
Fasenra (benralizumab) is a prescription drug that’s used to treat conditions such as eosinophilic asthma. Fasenra is given as an injection under your skin. This drug should not be used in certain ...
GlaxoSmithKline’s Nucala needs a win in its fight against AstraZeneca’s Fasenra. Now, it can at least tout a first-data advantage in a rare inflammatory disease. In a phase 3 study, the rate of ...
AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback